Back to top
more

Gilead Sciences (GILD)

(Delayed Data from NSDQ)

$73.51 USD

73.51
8,119,563

+0.21 (0.29%)

Updated Jul 18, 2024 04:00 PM ET

After-Market: $73.37 -0.14 (-0.19%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

New Strong Sell Stocks for March 12th

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Gilead (GILD) Announces Positive Long-Term Results on Descovy

Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.

Biotech Stock Roundup: NVAX, CANF Up on Coronavirus Treatment Updates & More

The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Regeneron (REGN) Gains from Focus on Coronavirus Treatments

Regeneron's (REGN) shares grow year to date owing to focus on developing a treatment for combating the novel coronavirus.

Why Is Gilead (GILD) Up 15.4% Since Last Earnings Report?

Gilead (GILD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Alnylam, Vir Collaborate on RNAi Therapy for Coronavirus

Alnylam (ALNY) expands its collaboration pact with Vir Biotechnology to develop RNAi therapeutics targeting SARS-CoV-2, the virus that induces Covid-19. Stock gains.

Inovio Surges on Expedited Timeline for Coronavirus Vaccine

Inovio (INO) to initiate human clinical studies on INO-4800, its DNA vaccine, this April, for the treatment of the deadly coronavirus. The stock price shoots up.

Biotech Stock Roundup: GILD to Buy Forty Seven, Pipeline Updates From BIIB & More

The biotech sector was in focus with new drug approvals, acquisitions and regular pipeline updates from quite a few companies.

Are Options Traders Betting on a Big Move in Gilead (GILD) Stock?

Investors need to pay close attention to Gilead (GILD) stock based on the movements in the options market lately.

Gilead to Buy Immuno-Oncology Company Forty Seven for $4.9B

Gilead (GILD) looks to strengthen its immuno-oncology research and development portfolio with the acquisition of Forty Seven.

Kinjel Shah headshot

Trump Asks Pharma Firms to Step Up Coronavirus Vaccine Work

President Donald Trump asks pharmaceutical companies working on making vaccines or treatments for coronavirus to accelerate development.

Pfizer Plans Coronavirus Therapy, Progresses With Tanezumab BLA

Pfizer (PFE) identifies potential antiviral compounds to develop a treatment for coronavirus disease. The FDA accepts regulatory application seeking approval for tanezumab for osteoarthritis.

Kinjel Shah headshot

5 Biotechs That Escaped the Coronavirus Onslaught Last Week

Here we discuss 5 biotech stocks that outperformed the industry amid the U.S. market slump.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Madeleine Johnson headshot

These 6 Drug Companies are Testing a Coronavirus Vaccine

As the coronavirus outbreak continues to spread, some of the biggest drug companies are moving closer to finding a vaccine.

Gilead Sciences (GILD) Surges: Stock Moves 6.6% Higher

Gilead Sciences (GILD) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

5 Drug/Biotech Stocks Likely to Beat Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks that are poised to beat on earnings in the fourth quarter.

Bristol-Myers' (BMY) CAR T Cell Therapy Gets Priority Review

Bristol-Myers' (BMY) BLA for lisocabtagene maraleucel gets Priority Review from the FDA.

J&J (JNJ) Signs Deal With HHS to Develop Coronavirus Vaccine

Johnson & Johnson (JNJ) expands its agreement with BARDA, part of U.S. Department of Health and Human Services for accelerated development of a vaccine for the newly found coronavirus.

Sweta Jaiswal, FRM headshot

Can Biotech ETFs Gain on Mixed Q4 Earnings Results?

Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry, post their Q4 earnings releases.

Western Union (WU) Q4 Earnings and Revenues Lag Estimates

Western Union (WU) delivered earnings and revenue surprises of -11.63% and -1.00%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

VAREX IMAGING (VREX) Q1 Earnings Miss Estimates

VAREX IMAGING (VREX) delivered earnings and revenue surprises of -25.00% and 4.87%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Diodes (DIOD) Q4 Earnings and Revenues Top Estimates

Diodes (DIOD) delivered earnings and revenue surprises of 3.17% and 0.39%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Gilead's BLA for CAR T Cell Therapy Gets FDA Acceptance

The FDA accepts Gilead's (GILD) BLA for its second CAR T cell therapy, KTE-X19.